| | | | | | Präparat | Packungsgrösse | EFP | PP | SB | TK | Zusammensetzung | Zulassungsinhaber | Kat. | | | | |
|---|
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | U | V | X | Z |
| L | | FI | PI | BM | Subutex 0,4 mg | 7 Tablette(n) | 2.97 | 7.50 | 10% | | Sublingualtabletten: Buprenorphinum | Indivior Schweiz AG | A+ / SL / SO | FB | | G |  |
| L | | FI | PI | BM | Subutex 2 mg | 28 Tablette(n) | 25.23 | 45.40 | 10% | | Sublingualtabletten: Buprenorphinum 2 mg | Indivior Schweiz AG | A+ / SL / SO | FB | | G | |
| L | | FI | PI | BM | Subutex 8 mg | 28 Tablette(n) | 90.60 | 120.55 | 10% | | Sublingualtabletten: Buprenorphinum 8 mg | Indivior Schweiz AG | A+ / SL / SO | FB | | G | |
| L | | FI | PI | BM | Seresta | 20 Tablette(n) | 1.96 | 6.35 | 10% | | Tabletten: Oxazepamum 15 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G | |
| L | | FI | PI | BM | Seresta | 50 Tablette(n) | 4.26 | 9.00 | 10% | | Tabletten: Oxazepamum 15 mg | Viatris Pharma GmbH | B / SL / SO | FB | | G | |
| L | | FI | PI | BM | Sevre-Long 30 mg | 30 Kapsel(n) | 20.28 | 39.70 | 10% | | Retard-Kapseln: Morphini Sulfas Pentahydricus 30 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | FI | PI | BM | Sevre-Long 60 mg | 30 Kapsel(n) | 33.27 | 54.65 | 10% | | Retard-Kapseln: Morphini Sulfas Pentahydricus 60 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | FI | PI | BM | Sevre-Long 120 mg | 30 Kapsel(n) | 54.52 | 79.05 | 10% | | Retard-Kapseln: Morphini Sulfas Pentahydricus 120 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | FI | PI | BM | Sevre-Long 200 mg - T | 30 Kapsel(n) | 60.92 | 86.40 | 10% | | Retard-Kapseln: Morphini Sulfas Pentahydricus 200 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| | | FI | PI | BM | Sevredol 10 mg | 20 Tablette(n) | 7.62 | 16.95 | 10% | | Filmtabletten: Morphini Sulfas Pentahydricus 10 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | | G | |
| L | | FI | PI | BM | Seresta forte | 20 Tablette(n) | 4.79 | 9.60 | 10% | | Tabletten: Oxazepamum 50 mg | Viatris Pharma GmbH | B / SL | FB | | G | |
| L | | FI | PI | BM | Seresta forte | 100 Tablette(n) | 18.58 | 37.75 | 10% | | Tabletten: Oxazepamum 50 mg | Viatris Pharma GmbH | B / SL | FB | | G | |
| | | FI | PI | BM | Stilnox CR 6.25 mg | 14 Tablette(n) | 1.91 | 6.30 | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | | G | |
| | | FI | PI | BM | Stilnox CR 6.25 mg | 28 Tablette(n) | 3.41 | 8.00 | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | | G | |
| | | FI | PI | BM | Stilnox CR 12.5 mg | 14 Tablette(n) | 3.23 | 7.80 | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | | G | |
| | | FI | PI | BM | Stilnox CR 12.5 mg | 28 Tablette(n) | 5.77 | 14.85 | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | | G | |
| | | FI | | BM | Sufenta | 5 1 Ampulle(n) à 2 ml | PA | PA | k.A. | | Injektionslösung: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | FI | | BM | Sufenta | 5 1 Ampulle(n) à 10 ml | PA | PA | k.A. | | Injektionslösung: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | FI | | BM | Sufenta forte | 5 1 Ampulle(n) à 1 ml | PA | PA | k.A. | | Injektionslösung: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | FI | | BM | Sufenta forte | 5 1 Ampulle(n) à 5 ml | PA | PA | k.A. | | Injektionslösung: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | FI | PI | BM | Subutex 0,4 mg | 28 Tablette(n) | PA | PA | k.A. | | Sublingualtabletten: Buprenorphinum | Indivior Schweiz AG | A+ | FB | | G | |
| | | FI | PI | BM | Subutex 2 mg | 7 Tablette(n) | 7.04 | 16.30 | k.A. | | Sublingualtabletten: Buprenorphinum 2 mg | Indivior Schweiz AG | A+ | FB | | G | |
| | | FI | PI | BM | Subutex 8 mg | 7 Tablette(n) | 24.58 | 44.60 | k.A. | | Sublingualtabletten: Buprenorphinum 8 mg | Indivior Schweiz AG | A+ | FB | | G | |
| | | FI | PI | BM | Stilnox ‐ F - T | 10 Tablette(n) | 2.78 | 7.30 | k.A. | | Tabletten teilbar: Zolpidemi Tartras 10 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | FI | PI | BM | Stilnox ‐ F - T | 30 Tablette(n) | 7.20 | 16.45 | k.A. | | Tabletten teilbar: Zolpidemi Tartras 10 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | FI | PI | BM | Stilnox CR 6.25 mg | 7 Tablette(n) | PA | PA | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
| | | FI | PI | BM | Stilnox CR 12.5 mg | 7 Tablette(n) | PA | PA | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B | FB | | G | |
